Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214064) titled 'Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation' on Oct. 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University Hospital Tuebingen
Condition:
AML (Acute Myeloid Leukemia)
MDS/AML
MDS (Myelodysplastic Syndrome)
Intervention:
Drug: RIC regimen
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: January 2026
Target Sample Size: 27
Countries of Recruitment:
Germany
To know more, visit...